Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
The objective of this study is to assess the efficacy and safety of talabostat and rituximab in patients with advanced CLL who failed to respond, or have progressed following a prior response, to a fludarabine regimen.
Chronic Lymphocytic Leukemia
DRUG: Talabostat mesylate (PT-100) tablets|DRUG: Rituximab
Completion date provided represents the completion date of the grant per OOPD records